SARS-CoV consists of four major proteins. The S protein is a membrane glycoprotein consisting of two structural domains. It is the main antigenic protein and is responsible for membrane fusion and receptor binding. S proteins are mainly used in the development of diagnostic agents and as immunogens for vaccine design. Peptide vaccines based on S proteins have been found to induce a broad spectrum of T-cell immunity. M proteins are the most abundant glycoproteins in viral particles and play an important role in viral particle formation. Studies have shown that M proteins or recombinant proteins expressing M proteins are capable of inducing antibody responses during CoV infection. Currently, S and M proteins can be obtained by genetic engineering production. The development of vaccines based on S and M proteins is also a hot research topic.
Fig.1 Structure of a SARSr-CoV virion. (Wikipedia)
CD BioGlyco has extensive experience in sugar-related vaccine development. Recombinant Glycoprotein Vaccines are simpler and safer than other vaccines. It is not only possible to realize large-scale production but also requires less storage and transportation conditions due to better stability. Currently, protein subunit vaccines against SARS-CoV can be categorized into three types: S-protein vaccines, receptor binding domain (RBD) vaccines, and multi-epitope peptide vaccines. Among them, S protein is the most used target antigen in SARS-CoV vaccine development. Recombinant M proteins can be used as antigens to detect infection with the corresponding CoV and to prepare vaccines. We provide glycoprotein vaccine development services based on S and M proteins.
We produce S and M proteins through genetic engineering. After cloning the S and M genes, recombinant expression plasmids are constructed for protein expression. Eukaryotic expression systems such as insect cells and Yeast Expression Systems are applied for expression. After expression, we characterize them. After that, we evaluate the effectiveness and safety of the vaccine by in vivo experiments. The addition of effective adjuvants, nanoparticle delivery systems, and immunogenic carrier proteins can enhance the immunogenicity of the vaccine. During the development of the vaccine, we will also study the effect of different adjuvants on its effectiveness.
Fig.2 Process of SARS-CoV protein vaccine development. (CD BioGlyco)
CD BioGlyco has a range of sugar-related vaccine development services. Our well-established sugar-related Vaccine Development Platform helps advance your research process. Feel free to contact us for detailed steps for vaccine development. We look forward to providing you with glycoprotein vaccine development services.
References
